Federal Register / Vol. 73, No. 155 / Monday, August 11, 2008 / Notices 46627 

guidelines which have been 

promulgated by the Department of 

Health and Human Services (HHS) as a 

final rule, advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule, 

advice on the scientific validity and 

quality of dose estimation and 

reconstruction efforts being performed 

for purposes of the compensation 

program, and advice on petitions to add 

classes of workers to the Special 

Exposure Cohort. 

In December 2000, the President 

delegated responsibility for funding, 

staffing, and operating the Advisory 

Board to HHS, which subsequently 

delegated this authority to the CDC. 

NIOSH implements this responsibility 

for CDC. The charter was issued on 

August 3, 2001, renewed at appropriate 

intervals, and will expire on August 3, 

2009. 

Purpose: This Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose (c) upon 

request by the Secretary, HHS, advising 

the Secretary on whether there is a class 

of employees at any Department of 

Energy facility who were exposed to 

radiation but for whom it is not feasible 

to estimate their radiation dose, and on 

whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of 

this class. 

Matters To Be Discussed: The agenda 

for the Advisory Board meeting 

includes: NIOSH Program Status 

Update; Special Exposure Cohort (SEC) 

Petitions for: Pantex; Connecticut 

Aircraft Nuclear Engine Laboratory 

(CANEL); SEC Petition Updates: 

Chapman Valve; Special Exposure 

Cohort (SEC) Petition Status Update(s); 

Department of Labor (DOL) Update; 

Department of Energy (DOE) Update; 

Work Group reports; Subcommittee on 

Dose Reconstruction Reviews Report; 

and Board Future Plans and Schedules. 

The agenda is subject to change as 

priorities dictate. 

In the event an individual cannot 

attend, written comments may be 

submitted according the policy 

provided below. Any written comments 

received will be provided at the meeting 

and should be submitted to the contact 

person below well in advance of the 

meeting. 

Policy on Redaction of Board Meeting 

Transcripts (Public Comment), if a 

person making a comment gives his or 

her name, no attempt will be made to 

redact that name. NIOSH will take 

reasonable steps to ensure that 

individuals making public comment are 

aware of the fact that their comments 

(including their name, if provided) will 

appear in a transcript of the meeting 

posted on a public Web site. Such 

reasonable steps include: (a) A 

statement read at the start of each public 

comment period stating that transcripts 

will be posted and names of speakers 

will not be redacted; (b) A printed copy 

of the statement mentioned in (a) above 

will be displayed on the table where 

individuals sign up to make public 

comment; (c) A statement such as 

outlined in (a) above will also appear 

with the agenda for a Board Meeting 

when it is posted on the NIOSH Web 

site; (d) A statement such as in (a) above 

will appear in the Federal Register 

notice that announces Board and 

Subcommittee meetings. If an 

individual in making a statement 

reveals personal information (e.g., 

medical information) about themselves 

that information will not usually be 

redacted. The NIOSH Freedom of 

Information Act coordinator will, 

however, review such revelations in 

accordance with the Freedom of 

Information Act and the Federal 

Advisory Committee Act and if deemed 

appropriate, will redact such 

information. All disclosures of 

information concerning third parties 

will be redacted. If it comes to the 

attention of the Designated Federal 

Officer (DFO) that an individual wishes 

to share information with the Board but 

objects to doing so in a public forum, 

the DFO will work with that individual, 

in accordance with the Federal 

Advisory Committee Act, to find a way 

that the Board can hear such comments. 

Contact Person for More Information: 

Zaida Burgos, Committee Management 

Specialist, NIOSH, CDC, 1600 Clifton 

Road, Atlanta, Georgia 30033, 

Telephone (404) 498–2548 Toll Free: 

(800) CDC–INFO, E-mail ocas@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: August 4, 2008. 

Daniel Riedford, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E8–18426 Filed 8–8–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Service 

Administration 

Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages (ACICBL). 

Dates and Times: September 10, 2008, 

11 a.m.–4 p.m., EST., September 11, 2008, 

11 a.m.–4 p.m., EST. 

Place: (Web Conference). 

Status: The meeting will be open to the 

public; Web conference access limited only 

by availability of telephone ports. 

Purpose: The Committee will be focusing 

on rural issues and how the Title VII 

Interdisciplinary, Community-Based Training 

Grant Programs identified under sections 

751–756, Part D of the Public Health Service 

Act can respond to the current rural 

healthcare workforce needs. The Committee 

has invited speakers to highlight various 

topics related to rural healthcare workforce 

issues including, but not limited to, 

discipline specific shortages; recruitment and 

retention; health professions training; faculty 

development; telemedicine; and other 

specific rural health care issues. The meeting 

will afford committee members with the 

opportunity to identify and discuss the 

current status of the healthcare workforce in 

rural America and formulate appropriate 

recommendations to the Secretary and to the 

Congress regarding a variety of training 

strategies to address the health workforce 

shortage issues. 

Agenda: The ACICBL agenda includes an 

overview of the Committee’s general business 

activities, presentations by experts on rural 

healthcare workforce related issues, and 

discussion sessions specific for the 

development of recommendations to be 

addressed in the Eighth Annual ACICBL 

Report. 

Agenda items are subject to change as 

dictated by the priorities of the Committee. 

Supplementary Information: The ACICBL 

will meet on Wednesday, September 10 and 

Thursday, September 11, 2008 from 11 a.m. 

to 4 p.m. (EST) via Intercall LiveMeeting Web 

conference. To join online, click the link 

below. Once connected call the number 

below and use the same conference ID to be 

connected to the call. If you have not joined 

an Intercall LiveMeeting Web conference 

before, please log in 20 minutes before the 

meeting as you may need to install an 

Intercall reader to access the Web conference. 

Meeting Link: https:// 

psa.on.raindance.com/confmgr/ 

public_unsched.jsp?confId=7829159. 

Meeting Phone #: (888) 272–7337. 

Conference ID: 7829159. 

Meeting Subject: HRSA Advisory 

Committee on Interdisciplinary, CommunityBased Linkages (ACICBL). 


rmajette on PRODPC74 with NOTICES
46628 Federal Register / Vol. 73, No. 155 / Monday, August 11, 2008 / Notices 

Moderator: Ashley Golden 

Moderator E-mail: a_golden@teampsa.com. 

For Further Information Contact: Anyone 

requesting information regarding the 

Committee should contact Louis D. 

Coccodrilli, Designated Federal Official for 

the ACICBL, Bureau of Health Professions, 

Health Resources and Services 

Administration, Parklawn Building, Rm. 9–

36, 5600 Fishers Lane, Rockville, Maryland 

20857; (301) 443–6950 or 

lcoccodrilli@hrsa.gov. Marie Ulysse, HRSA 

Scholar, can also be contacted for inquiries 

at (301) 443–6529 or mulysse@hrsa.gov. 

Dated: August 4, 2008. 

Alexandra Huttinger, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. E8–18393 Filed 8–8–08; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 

Comment Request; The Prevalence 

and Incidence of HIV Molecular 

Variants and Their Correlation With 

Risk Behaviors and HIV Treatment in 

Brazilian Blood Donors 

Summary: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Heart, Lung, and Blood Institute 

(NHLBI), the National Institutes of 

Health (NIH) has submitted to the Office 

of Management and Budget (OMB) a 

request to review and approve the 

information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on May 29, 2008, pages 30951–

30952 and allowed 60 days for public 

comment. The purpose of this notice is 

to allow an additional 30 days for public 

comment. The National Institutes of 

Health may not conduct or sponsor, and 

the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a current valid 

OMB control number. 

Proposed Collection: Title: The 

Prevalence and Incidence of HIV 

Molecular Variants and Their 

Correlation With Risk Behaviors and 

HIV Treatment in Brazilian Blood 

Donors. Type of Information Collection 

Request: New. Need and Use of 

Information Collection: Establishing and 

monitoring viral prevalence and 

incidence rates, and identifying risk 

behaviors for HIV incidence among 

blood donors, are critical to assessing 

and reducing risk of HIV transmission 

through blood transfusion. Identifying 

donation samples from donors with 

recent HIV infection is particularly 

critical as it enables characterization of 

the viral subtypes currently transmitted 

within the screened population and 

hence most likely to ‘‘break-through’’

routine screening measures (i.e., periseroconversion window period 

donations). Molecular surveillance of 

incident HIV infections in blood donors 

not only characterizes genotypes of 

recently infected donors for purposes of 

blood safety, but also enables 

documentation of the rates of primary 

transmission of anti-viral drug resistant 

strains in the community, serving a 

public health role in identifying new 

HIV infections for anti-retroviral 

treatment. Both a prospective 

surveillance and a case-control design 

are proposed to enroll all eligible HIV 

seropositives detected at three blood 

centers in Brazil (Sa ̃o Paulo, Belo 

Horizante, and Recı ́fe) plus a satellite 

center in Rio de Janeiro. A comparison 

of epidemiological risk profiles will be 

made between the seropositive donors 

and a group of randomly selected 

seronegative donors. 

There are three study aims. 

Laboratory studies (LS–EIA testing and 

sequencing of pol region) on linked 

specimens from all enrolled HIV cases, 

will allow for estimation of HIV 

prevalence and incidence relative to 

genotype and putative route of 

infection. Data derived from molecular 

genotyping, including drug resistant 

genotypes, will be provided, along with 

counseling, to all enrolled HIV positive 

donors to facilitate their clinical care via 

referral to the Brazilian national HIV 

treatment system. Our findings will be 

compared to trends in prevalence, 

incidence and molecular variants from 

studies of the general population and 

high risk populations in Brazil, thus 

allowing for broad monitoring of the 

HIV epidemic in Brazil and assessment 

of the impact of donor selection criteria 

on these parameters. Finally, HIV cases 

and a group of controls, through 

responses to a questionnaire, will 

provide data on HIV risk behaviors 

among prospective blood donors. This 

HIV risk behavior data will be used as 

covariates in the molecular surveillance 

analyses described above, as well as aid 

in assessing whether modifications may 

be needed to Brazil’s routine blood 

center operational donor screening 

questionnaire. 

The study participants will return to 

their local blood center for the 

administration of an informed consent 

form, explaining the confidential nature 

of the research study as well as the risks 

and benefits to their participation. Once 

enrolled, they will be asked to complete 

the self-administered risk factor 

questionnaire. In addition, a small blood 

sample will be collected from each HIV 

seropositive participant to be used for 

the genotyping and drug resistance 

testing. The results of the drug 

resistance testing will be communicated 

back to the seropositive participants 

during an in-person counseling session 

at the blood center. 

Defining prevalence and incidence in 

blood donors and residual risk of HIV 

transmission by transfusions may lead 

to new regulations and blood safety 

initiatives in Brazil. The data can be 

used to project the yield, safety impact 

and cost effectiveness of implementing 

enhanced testing strategies such as 

combination antigen-antibody assays 

and/or NAT. Determination of HIV risk 

factors in donors (first time versus 

repeat donor status; volunteer versus 

replacement status; demographics and 

risk behaviors) will support policy 

discussions over strategies to recruit the 

safest possible donors in Brazil. The 

findings from this project will also 

complement similar monitoring of HIV 

prevalence, incidence, transfusion risk 

and molecular variants in the U.S. and 

other funded international REDS–II 

sites, thus allowing direct comparisons 

of these parameters on a global level. 

Frequency of Response: Once. 

Affected Public: Individuals. Type of 

Respondents: Adult Blood Donors. The 

annual reporting burden is as follows: 

Estimated Number of Respondents: 

2,000; Estimated Number of Responses 

per Respondent: 1; Average Burden of 

Hours per Response: 0.40 (including 

administration of the informed consent 

form and questionnaire completion 

instructions); and Estimated Total 

Annual Burden Hours Requested: 800. 

The annualized cost to respondents is 

estimated at: $5,200 (based on $6.50 per 

hour). There are no Capital Costs to 

report. There are no Operating or 

Maintenance Costs to report. 


rmajette on PRODPC74 with NOTICES